Organization
Nanjing Legend Biotech
2 clinical trials
Clinical trial
A Phase 2, Open-Label Study of LCAR-B38M CAR-T Cells, a Chimeric Antigen Receptor T-cell (CAR-T) Therapy Directed Against BCMA in Chinese Subjects With Relapsed or Refractory Multiple MyelomaStatus: Recruiting, Estimated PCD: 2026-02-16
Clinical trial
A Clinical Study of Legend Biotech BCMA-chimeric Antigen Receptor Technology in Treating Relapsed/Refractory (R/R) Multiple Myeloma PatientsStatus: Active (not recruiting), Estimated PCD: 2023-12-31